533 Results

Genomics of lethal prostate cancer at diagnosis and castration-resistance.

Genomics of primary prostate cancer differs from that of metastatic castration-resistant prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer biopsies from patients who developed mCRPC...

Silencing TTK expression inhibits the proliferation and progression of prostate cancer.

Purpose: The main objective of our study was to explore changes in the expression levels of differentially expressed genes associated with prostate cancer progression and to design a series of experiments to verify the function of...

Proton versus photon-based radiation therapy for prostate cancer: emerging evidence and considerations in the era of value-based cancer care.

Background: Advances in radiation technology have transformed treatment options for patients with localized prostate cancer. The evolution of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy...

Diagnostic properties of total and free prostate-specific antigen to predict overall and clinically significant prostate cancer among men with low testosterone and prior negative biopsy.

Objective: To evaluate whether total serum PSA, free-PSA ratio and PSA density have similar diagnostic properties for detecting prostate cancer (PCa) and clinically-significant (cs) PCa in men with normal testosterone compared...

Role of Androgen Receptor in Prostate Cancer: A Review.

This review focuses on the functions of AR in prostate cancer and the development of CRPC and promising new agents against CRPC.

Increased expression of miR-153 predicts poor prognosis for patients with prostate cancer.

Deregulation of miR-153 has recently been observed in several common human cancer, while miR-153 serves an oncogene or tumor suppressive role in different cancer types. Previously, miR-153 has been identified to be overexpressed in...

Prostate radiotherapy in newly diagnosed metastatic prostate cancer.

Purpose of review: The aim of this article is to review the role of prostate radiotherapy in the multimodal management of newly diagnosed metastatic hormone naïve prostate cancer.

Exploitation of CD133 for the targeted imaging of lethal prostate cancer.

Purpose: Aggressive variant prostate cancer (AVPC) is a non-androgen receptor-driven form of disease that arises in men who have failed standard-of-care therapies. Therapeutic options for AVPC are limited, and the development of...

Prostate-specific membrane antigen guided surgery.

Since its introduction in the diagnostic pathway of prostate cancer management, prostate-specific membrane antigen (PSMA)-ligand positron-emission tomography (PET) has demonstrated great potential.

Prostate cancer in young men: An emerging young adult and older adolescent challenge.

Background: Recent observations suggest that prostate cancer is an increasing disease among older adolescents and young adults.

Load more